CONSORT 2025 statement: Updated guideline for reporting randomised trials
PLOS Medicine · 14.04.2025 · 22 (4) · e1004587
DOI: 10.1371/journal.pmed.1004587 ↗Kurz gefasst
Leitlinie in der Zeitschrift PLOS Medicine, online erschienen am 14.04.2025. Verfasst von Sally Hopewell und 38 weiteren Autor:innen. Beteiligte Einrichtung: Oxford Clinical Trials Research Unit, Centre for Statistics in Medicine, University of Oxford, Oxford, United Kingdom. Hauptthemen laut MEDLINE: Randomized Controlled Trials as Topic, Guidelines as Topic, Research Report, Publishing. Die Arbeit wurde bisher 111-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council.
Abstract (Originalsprache)
Background
Well designed and properly executed randomised trials are considered the most reliable evidence on the benefits of healthcare interventions. However, there is overwhelming evidence that the quality of reporting is not optimal. The CONSORT (Consolidated Standards of Reporting Trials) statement was designed to improve the quality of reporting and provides a minimum set of items to be included in a report of a randomised trial. CONSORT was first published in 1996, then updated in 2001 and 2010. Here, we present the updated CONSORT 2025 statement, which aims to account for recent methodological advancements and feedback from end users.
Methods
We conducted a scoping review of the literature and developed a project-specific database of empirical and theoretical evidence related to CONSORT, to generate a list of potential changes to the checklist. The list was enriched with recommendations provided by the lead authors of existing CONSORT extensions (Harms, Outcomes, Non-pharmacological Treatment), other related reporting guidelines (TIDieR) and recommendations from other sources (e.g., personal communications). The list of potential changes to the checklist was assessed in a large, international, online, three-round Delphi survey involving 317 participants and discussed at a two-day online expert consensus meeting of 30 invited international experts.
Results
We have made substantive changes to the CONSORT checklist. We added seven new checklist items, revised three items, deleted one item, and integrated several items from key CONSORT extensions. We also restructured the CONSORT checklist, with a new section on open science. The CONSORT 2025 statement consists of a 30-item checklist of essential items that should be included when reporting the results of a randomised trial and a diagram for documenting the flow of participants through the trial. To facilitate implementation of CONSORT 2025, we have also developed an expanded version of the CONSORT 2025 checklist, with bullet points eliciting critical elements of each item.
Conclusions
Authors, editors, reviewers, and other potential users should use CONSORT 2025 when writing and evaluating manuscripts of randomised trials to ensure that trial reports are clear and transparent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Oxford Clinical Trials Research Unit, Centre for Statistics in Medicine, University of Oxford, Oxford, United Kingdom.
- Department of Medicine, Women's College Research Institute, University of Toronto, Toronto, Ontario, Canada.
- United Kingdom EQUATOR Centre, Centre for Statistics in Medicine, University of Oxford, Oxford, United Kingdom.
- Department of Clinical Research, Centre for Evidence-Based Medicine Odense and Cochrane Denmark, University of Southern Denmark, Odense, Denmark.
- Open Patient data Explorative Network, Odense University Hospital, Odense, Denmark.
- Centre for Journalology, Clinical Epidemiology Programme, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
ORCID-Profile: Sally Hopewell, An-Wen Chan, Gary S Collins, Asbjørn Hróbjartsson, David Moher, Kenneth F Schulz, Ruth Tunn, Rakesh Aggarwal, Michael Berkwits, Jesse A Berlin, Nita Bhandari, Nancy J Butcher, Marion K Campbell, Runcie C W Chidebe, Diana Elbourne, Andrew Farmer, Dean A Fergusson, Robert M Golub, Tammy C Hoffmann, John P A Ioannidis, Rachel L Knowles, Sarah E Lamb, Martin Offringa, Dawn P Richards, Frank W Rockhold, Nandi L Siegried, Sophie Staniszewska, Rod S Taylor, Lehana Thabane, David Torgerson, Sunita Vohra, Ian R White, Isabelle Boutron
Förderung
- Medical Research Council
Zitieren
APA
Hopewell, S., Chan, A. W., Collins, G. S., Hróbjartsson, A., Moher, D., Schulz, K. F., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., Bhandari, N., Butcher, N. J., Campbell, M. K., Chidebe, R. C. W., Elbourne, D., Farmer, A., Fergusson, D. A., Golub, R. M., Goodman, S. N., …, & Boutron, I. (2025). CONSORT 2025 statement: Updated guideline for reporting randomised trials. PLOS Medicine, 22(4), e1004587. https://doi.org/10.1371/journal.pmed.1004587
Vancouver
Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, et al. CONSORT 2025 statement: Updated guideline for reporting randomised trials. PLOS Medicine. 2025;22(4):e1004587. doi:10.1371/journal.pmed.1004587
BibTeX
@article{Hopewell2025,
author = {Hopewell, Sally and Chan, An-Wen and Collins, Gary S and Hróbjartsson, Asbjørn and Moher, David and Schulz, Kenneth F and Tunn, Ruth and Aggarwal, Rakesh and Berkwits, Michael and Berlin, Jesse A and Bhandari, Nita and Butcher, Nancy J and Campbell, Marion K and Chidebe, Runcie C W and Elbourne, Diana and Farmer, Andrew and Fergusson, Dean A and Golub, Robert M and Goodman, Steven N and Hoffmann, Tammy C and Ioannidis, John P A and Kahan, Brennan C and Knowles, Rachel L and Lamb, Sarah E and Lewis, Steff and Loder, Elizabeth and Offringa, Martin and Ravaud, Philippe and Richards, Dawn P and Rockhold, Frank W and Schriger, David L and Siegried, Nandi L and Staniszewska, Sophie and Taylor, Rod S and Thabane, Lehana and Torgerson, David and Vohra, Sunita and White, Ian R and Boutron, Isabelle},
title = {CONSORT 2025 statement: Updated guideline for reporting randomised trials},
journal = {PLOS Medicine},
year = {2025},
volume = {22},
number = {4},
pages = {e1004587},
doi = {10.1371/journal.pmed.1004587}
}
EUVIMED